In breast cancer, about 45%-55% showed low HER2 expression, i.e., immunohistochemistry (IHC) 1+, or IHC 2+ and no amplification of the HER2 gene by in situ hybridization (ISH) (6). The gene discussed is ERBB2; the disease is breast carcinoma.